Haoxi Health Technology Ltd

HAO tracks a cap-weighted index of Chinese small-cap stocks with float-adjusted market caps between $200 million and $1.5 billion.

Earnings data Q2 2024

Haoxi Health Technology Ltd. is a holding company, which engages in the provision of internet marketing solutions. It offers services for various industries to reduce risks, reduce operating costs, and ensure greater profits through in-depth insights into strategy, creativity, media integration, and industry development. The company was founded on August 5, 2022 and is headquartered in Beijing, China.

BEIJING, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Haoxi Health Technology Limited (the “Company” or “HAO”), an online marketing solution provider headquartered in Beijing, China, today reported its financial results for the fiscal year ended June 30, 2024.

Haoxi Health Technology Limited Reports Financial Results for Fiscal Year Ended June 30, 2024

BEIJING, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Haoxi Health Technology Limited (the “Company” or “HAO”), an online marketing solution provider headquartered in Beijing, China, today announced preliminary unaudited financial results for the fiscal year ended June 30, 2024 (“FY24”).

Haoxi Health Technology Limited Announces Preliminary Unaudited FY24 Financial Results with projected 72% Revenue Growth

BEIJING, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Haoxi Health Technology Limited (the “Company” or “HAO”), an online marketing solution provider headquartered in Beijing, China, today announced a strategic partnership with an AI platform, Gauss Intelligence (Beijing) Technology Co., Ltd., a subsidiary of Global Mofy AI Ltd (Nasdaq: GMM). This collaboration aims to leverage the advanced capabilities of Gausspeed, a cutting-edge generative AI platform, alongside HAO's extensive application scenarios to deliver transformative AI marketing solutions.

Haoxi Health Technology Limited and Global Mofy AI Ltd Announce Strategic Partnership to Innovate AI Marketing Solutions

BEIJING, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Haoxi Health Technology Limited (the “Company” or “HAO”), an online marketing solution provider headquartered in Beijing, China, today announced that it closed its previously announced underwritten follow-on offering of 4,000,000 units (each a “Unit,” and collectively, the “Units”) at a public offering price of $3.00 per Unit (the “Offering”). Each Unit consists of (i) one share of Class A Ordinary Share, par value $0.0001 per share (the “Class A Ordinary Share”) (or one pre-funded warrant to purchase one Class A Ordinary Share (the “Pre-Funded Warrant”)), (ii) one Series A warrant to purchase one Class A Ordinary Share (the “Series A Warrant”) initially, but five Class A Ordinary Shares on and after the Series B Exercise Date, and (iii) one Series B warrant to purchase four of Class A Ordinary Shares on and after the sixteenth (16th) calendar day (the “Series B Exercise Date”) following the closing of the Offering (the "Series B Warrant”, together with the Series A Warrant, the “Warrants”). The Units have no stand-alone rights and therefore are not certificated or issued as stand-alone securities. The Class A Ordinary Shares and related Warrants are issued separately in the Offering. The Company received aggregate gross proceeds of $12,000,000 from the Offering, before deducting underwriting discounts and other offering expenses, excluding the exercise of any Warrants.

Haoxi Health Technology Limited Announces the Closing of a $12 Million Underwritten Follow-on Public Offering

BEIJING, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Haoxi Health Technology Limited (the “Company” or “HAO”), an online marketing solution provider headquartered in Beijing, China, today announced the pricing of its underwritten follow-on public offering (the "Offering") of 4,000,000 units (each a “Unit,” and collectively, the “Units”) at an offering price of $3.00 per Unit (the “Public Offering Price”) for total gross proceeds of $12,000,000, before deducting underwriting discounts and other offering expenses. Each Unit consists of (i) one share of Class A Ordinary Share, par value $0.0001 per share (the “Class A Ordinary Share”) (or one pre-funded warrant to purchase one Class A Ordinary Share (the “Pre-Funded Warrant”)), (ii) one Series A warrant to purchase one Class A Ordinary Share (the “Series A Warrant”) (subject to certain adjustments therein), and (iii) one Series B warrant to purchase such number of Class A Ordinary Share described in the prospectus of the Offering (the "Series B Warrant”, together with the Series A Warrant, the “Warrants”). The Warrants will have a term of 5 years from the closing date of the Offering (the “Closing Date”). The Series A Warrant is exercisable immediately upon issuance, or the Closing Date. The Series B Warrant is exercisable at any time on or after the sixteenth (16th) calendar day from the Closing Date (the “Series B Exercise Date”). The Series A Warrants have an initial exercise price of $3.00 per Class A Ordinary Share. On the Series B Exercise Date, the exercise price of the Series A Warrant will be adjusted to $0.60 and the maximum number of Class A Ordinary Shares issuable upon exercise of the Series A Warrants will be adjusted to 20,000,000 shares. The exercise price of the Series B Warrants is $0.0001 per Class A Ordinary Share. The maximum number of shares issuable upon exercise of the Series B Warrants will be 16,000,000 shares. The Units have no stand-alone rights and will not be certificated or issued as stand-alone securities. The Class A Ordinary Shares, the Pre-Funded Warrants, and related Warrants are immediately separable and will be issued separately in the Offering.

Haoxi Health Technology Limited Announces Pricing of a $12 Million Underwritten Follow-on Public Offering

BEIJING--(BUSINESS WIRE)--HAO has established a dedicated service team, collaborating closely with medical aid organizations to assess frontline medical supply requirements.

Haoxi Health Technology Limited Facilitates International Humanitarian Aid Efforts Amid Global Challenges

BEIJING, May 31, 2024 (GLOBE NEWSWIRE) -- Haoxi Health Technology Limited (the “Company” or “HAO”), an online marketing solution provider headquartered in Beijing, China, today reported its unaudited financial results for the six months ended December 31, 2023.

Haoxi Health Technology Limited Reports Unaudited Financial Results for The Six Months Ended December 31, 2023

BEIJING, May 07, 2024 (GLOBE NEWSWIRE) -- Haoxi Health Technology Limited (the “Company” or “HAO”), an online marketing solution provider headquartered in Beijing, China, today announced that Beijing Haoxi Digital Technology Co., Ltd. (“Haoxi Beijing”), a wholly-owned subsidiary of the Company, entered into a bidding data promotion rebate agreement (the “Rebate Agreement”) on April 29, 2024 with Jinan Yanling Biotechnology Co., Ltd. (“Yanling”) and its subsidiaries and affiliated companies (together, the “Clients”).

Haoxi Health Technology Limited Enters into Rebate Agreement with Clients on Advertising Placement Campaign

BEIJING, May 03, 2024 (GLOBE NEWSWIRE) -- Haoxi Health Technology Limited (the “Company” or “HAO”), an online marketing solution provider headquartered in Beijing, China, today announced that Beijing Haoxi Digital Technology Co., Ltd. (“Haoxi Beijing”), a wholly-owned subsidiary of the Company, entered into a Framework Contract for Cooperation on Information Placement on Media Platforms (the “Framework Contract”) on April 28, 2024 with Wuhan Yiya Simei Dental Clinic Co., Ltd. (“Yiya Dental”), a regional dentistry chain in China. This partnership underscores the Company's capabilities in delivering internet marketing solutions.

Haoxi Health Technology Limited Enters into Advertising Placement Service Framework Contract

AMC Entertainment

Sirius XM Holdings Inc

The most oversold stocks in the communication services sector presents an opportunity to buy into undervalued companies.

Top 3 Tech And Telecom Stocks Which Could Rescue Your Portfolio This Quarter - AMC Enter Hldgs (NYSE:AMC), Haoxi Health Technology (NASDAQ:HAO)

BEIJING, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Haoxi Health Technology Limited (the “Company” or “HAO”), an online marketing solution provider headquartered in Beijing, China, today announced the closing of its initial public offering (the "Offering") of 2,400,000 Class A ordinary shares (the "Ordinary Shares") at an initial public offering price of $4.00 per share for total gross proceeds of $9,600,000, before deducting underwriting discounts and other offering expenses. The Offering closed on January 30, 2024, and the Ordinary Shares began trading on Nasdaq Capital Market on January 26, 2024, under the ticker symbol "HAO". The Company has granted EF Hutton LLC (“EF Hutton”), the representative of the underwriters, an option, within 45 days from the closing date of the Offering, to purchase up to an additional 360,000 Ordinary Shares at the public offering price, less underwriting discounts, to cover the over-allotments, if any. The Offering has been conducted on a firm commitment basis.

Haoxi Health Technology Limited Announces Closing of $9,600,000 Initial Public Offering

BEIJING, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Haoxi Health Technology Limited (the “Company” or “HAO”), an online marketing solution provider headquartered in Beijing, China, today announced the pricing of its initial public offering (the "Offering") of 2,400,000 Class A ordinary shares (the "Ordinary Shares") at a public offering price of $4.00 per share (“Public Offering Price”) for total gross proceeds of $9,600,000, before deducting underwriting discounts and other offering expenses. The Ordinary Shares have been approved for listing on the Nasdaq Capital Market and are expected to commence trading on January 26, 2024, under the ticker symbol "HAO".

Haoxi Health Technology Limited Announces Pricing of Its Initial Public Offering

Haoxi Health Technology Limited has filed for an IPO to raise $13.5 million. The company provides online short-form video marketing solutions to healthcare advertisers in China. Due to its small size, thin capitalization, operational risks, low margin, and regulatory uncertainties, my outlook on the IPO is to Sell [Avoid].

News for Haoxi Health Technology Ltd Stock (HAO)